Share Prices & Company Research

Stockbroking

Oxford BioMedica

Current Price 1004.19p Bid 1000.00p Ask 1003.80p Change -4.40%
Last Updated: 22/06/2018 19:51. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Oxford BioMedica plc is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the Group) have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people.

Financial Highlights Year Ended 31/12/2017

Turnover
£37.59m
Operating Profit
£-5.67m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-3620.70

Key Personnel

Peter John Nolan
Chief Business Officer
John Andrew Dawson
Chief Executive Officer
Stuart Paynter
Chief Financial Officer
Dr Lorenzo Tallarigo
Non-Executive Chairman
Dr Heather Elizabeth Preston
Non-Executive Director
Martin Henry Diggle
Non-Executive Director
Dr Andrew John William Heath
Non-Executive Director
Stuart Jonathon Brodie Henderson
Non-Executive Director

Stock Details

EPIC
OXB
ISIN
GB00BDFBVT43
Shares in Issue
4,003,170,966
Market cap
£42,033.30m

Analyst Views (2)

Strong Buy
 
50.00%
Buy
 
0.00%
Hold
 
50.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1003.80p
Bid Price
1000.00p
Ask Price
1003.80p
Volume
613932
Change Today
-46.20p
% Change Today
-4.40%
Open
1039.20p
Previous Close
1003.80p
Intraday High
1057.61p
Intraday Low
982.44p
52 Week High
1062.60p
52 Week Low
5.29p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Oxford BioMedica Intra-day Chart

Oxford BioMedica News

News in this section is provided by MoneyAM

Director Deals - Oxford BioMedica PLC (OXB) 22 Jun 2018 | 13:15 Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC 13 Jun 2018 | 08:40 FTSE boosted by miners 06 Jun 2018 | 16:59 FTSE follows international indices higher 06 Jun 2018 | 12:01 Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC 06 Jun 2018 | 08:40 Oxford BioMedica inks up to $843m licensing agreement with Axovant Sciences 06 Jun 2018 | 08:10 Director Deals - Oxford BioMedica PLC (OXB) 23 May 2018 | 16:30 Oxford BioMedica plans share consolidation to improve liquidity 04 May 2018 | 09:11 Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC 02 May 2018 | 12:40 Director Deals - Oxford BioMedica PLC (OXB) 23 Apr 2018 | 12:50 Director Deals - Oxford BioMedica PLC (OXB) 11 Apr 2018 | 15:10 Director Deals - Oxford BioMedica PLC (OXB) 09 Apr 2018 | 11:00 Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC 09 Apr 2018 | 09:50 Director Deals - Oxford BioMedica PLC (OXB) 05 Apr 2018 | 14:45 Director Deals - Oxford BioMedica PLC (OXB) 22 Mar 2018 | 11:40 Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC 15 Mar 2018 | 09:20 Oxford BioMedica cuts EBITDA loss 15 Mar 2018 | 08:38 Director Deals - Oxford BioMedica PLC (OXB) 23 Feb 2018 | 15:25 Oxford BioMedica signs agreement with Bioverativ 15 Feb 2018 | 08:41 FTSE boosted by US and Asia gains 15 Feb 2018 | 08:38 Director Deals - Oxford BioMedica PLC (OXB) 23 Jan 2018 | 13:25 Oxford BioMedica notes treatment priority review 17 Jan 2018 | 09:37 Director Deals - Oxford BioMedica PLC (OXB) 20 Dec 2017 | 11:55 Director Deals - Oxford BioMedica PLC (OXB) 23 Nov 2017 | 15:45 Director Deals - Oxford BioMedica PLC (OXB) 23 Oct 2017 | 13:20 Director Deals - Oxford BioMedica PLC (OXB) 26 Sep 2017 | 15:10 Director Deals - Oxford BioMedica PLC (OXB) 22 Sep 2017 | 15:25 Director Deals - Oxford BioMedica PLC (OXB) 19 Sep 2017 | 09:15 Director Deals - Oxford BioMedica PLC (OXB) 19 Sep 2017 | 09:15 Broker Forecast - Peel Hunt issues a broker note on Oxford BioMedica PLC 19 Sep 2017 | 08:40

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Tangible Assets
25.4
27.5
Intangible Assets & Goodwill
0.1
1.3
Investments & Other Non-Current Assets
3.0
0.7
Total Non-Current Assets
28.4
29.5
Inventory
3.3
2.2
Trade & Receivables
17.1
6.9
Cash & Receivables
14.3
15.3
Other Current Assets & Assets Held for Resale
2.2
3.0
Total Assets
65.4
56.9

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Short Term Liabilities
21.8
9.3
Long Term Liabilities
37.5
35.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
59.3
44.3

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Net Assets
6.2
12.6

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Share Capital
31.1
30.9
Minority Interests
0.0
0.0
Retained Earnings
-182.7
-174.5
Share Premium Account
154.2
154.0
Other Equity
3.5
2.2
Total Equity
6.2
12.6

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Cashflow from Operating Activities
3.0
-5.1
Cashflow Before Financing
1.1
-11.5
Increase / Decrease in Cash
-1.0
6.0

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Turnover
37.6
27.8
Cost of Sales
18.4
11.8
Gross Profit
19.2
15.9
Operating Profit
-5.7
-11.3
Pre-Tax Profit
-11.8
-20.3
Profit / Loss for the Year
-9.0
-16.6
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.